David L Sultzer
Overview
Explore the profile of David L Sultzer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
1882
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bigio B, Lima-Filho R, Barnhill O, Sudo F, Drummond C, Assuncao N, et al.
Mol Psychiatry
. 2025 Jan;
PMID: 39774493
A major challenge in the development of more effective therapeutic strategies for Alzheimer's disease (AD) is the identification of molecular mechanisms linked to specific pathophysiological features of the disease. Importantly...
2.
Salazar C, Tallakson M, Corona M, Duran E, Russ E, Hoang D, et al.
Alzheimers Dement
. 2024 Aug;
20(10):7160-7173.
PMID: 39210635
Introduction: Alzheimer's disease (AD) disproportionately affects minoritized populations who remain underrepresented in AD trials. Methods: We partnered with local nursing community-based organizations to implement a culturally tailored educational intervention and...
3.
Yarns B, Jackson N, Alas A, Melrose R, Lumley M, Sultzer D
JAMA Netw Open
. 2024 Jun;
7(6):e2415842.
PMID: 38869899
Importance: Chronic pain is common and disabling in older adults, and psychological interventions are indicated. However, the gold standard approach, cognitive-behavioral therapy (CBT), produces only modest benefits, and more powerful...
4.
Koek R, Avecillas-Chasin J, Krahl S, Chen J, Sultzer D, Kulick A, et al.
J Psychiatr Res
. 2024 May;
175:131-139.
PMID: 38733927
Deep brain stimulation (DBS) holds promise for neuropsychiatric conditions where imbalance in network activity contributes to symptoms. Treatment-resistant Combat post-traumatic stress disorder (TR-PTSD) is a highly morbid condition and 50%...
5.
Sible I, Jang J, Sultzer D, Nation D
Am J Geriatr Psychiatry
. 2022 Apr;
30(10):1110-1119.
PMID: 35487831
Objectives: Depression is related to increased risk for dementia, possibly through links with cerebrovascular disease. Blood pressure variability is an emerging risk factor for cerebrovascular disease and dementia, but relationships...
6.
Sultzer D, Lim A, Gordon H, Yarns B, Melrose R
Alzheimers Res Ther
. 2022 Feb;
14(1):25.
PMID: 35130968
Background: Cholinergic neurotransmitter system dysfunction contributes to cognitive impairment in Alzheimer's disease and other syndromes. However, the specific cholinergic mechanisms and brain structures involved, time course of alterations, and relationships...
7.
Tariot P, Ballard C, Devanand D, Cummings J, Sultzer D
Lancet Neurol
. 2022 Jan;
21(2):114-115.
PMID: 35065031
No abstract available.
8.
Mortby M, Adler L, Aguera-Ortiz L, Bateman D, Brodaty H, Cantillon M, et al.
Am J Geriatr Psychiatry
. 2021 Jul;
30(2):119-147.
PMID: 34315645
Apathy is one of the most prevalent, stable and persistent neuropsychiatric symptom across the neurocognitive disorders spectrum. Recent advances in understanding of phenomenology, neurobiology and intervention trials highlight apathy as...
9.
Tariot P, Cummings J, Soto-Martin M, Ballard C, Erten-Lyons D, Sultzer D, et al.
N Engl J Med
. 2021 Jul;
385(4):309-319.
PMID: 34289275
Background: Patients with dementia due to neurodegenerative disease can have dementia-related psychosis. The effects of the oral 5-HT inverse agonist and antagonist pimavanserin on psychosis related to various causes of...
10.
Grill J, Raman R, Ernstrom K, Sultzer D, Burns J, Donohue M, et al.
JAMA Neurol
. 2020 Aug;
77(12):1504-1513.
PMID: 32777010
Importance: The goal of preclinical Alzheimer disease (AD) clinical trials is to move diagnosis and treatment to presymptomatic stages, which will require biomarker testing and disclosure. Objective: To assess the...